Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study

被引:27
|
作者
Kuwata, Hitoshi [1 ,2 ]
Yabe, Daisuke [1 ,3 ,4 ]
Murotani, Kenta [5 ]
Fujiwara, Yuuka [1 ]
Haraguchi, Takuya [1 ,2 ,3 ]
Kubota, Sodai [1 ,3 ]
Kubota-Okamoto, Saki [1 ,3 ]
Usui, Ryota [1 ,2 ]
Ishitobi, Minori [2 ]
Yamazaki, Yuji [1 ,2 ]
Hamamoto, Yoshiyuki [1 ,2 ]
Kurose, Takeshi [1 ,6 ]
Seino, Yusuke [7 ]
Yamada, Yuichiro [1 ,2 ]
Seino, Yutaka [1 ,2 ]
机构
[1] Kansai Elect Power Med Res Inst, Yutaka Seino Distinguished Ctr Diabet Res, Kobe, Hyogo, Japan
[2] Kansai Elect Power Hosp, Ctr Diabet Endocrinol & Metab, Osaka, Japan
[3] Gifu Univ, Grad Sch Med, Dept Diabet Endocrinol & Metab, Gifu, Japan
[4] Kobe Univ, Grad Sch Med, Div Mol & Metab Med, Kobe, Hyogo, Japan
[5] Kurume Univ, Grad Sch Med, Biostat Ctr, Kurume, Fukuoka, Japan
[6] Nakanoshima Clin, Osaka, Japan
[7] Fujita Hlth Univ, Dept Endocrinol & Metab, Toyoake, Aichi, Japan
关键词
Gastric emptying; GLP-1 receptor agonist; islet hormones; OPEN-LABEL; INCRETIN SECRETION; LIRAGLUTIDE; LIXISENATIDE; GLP-1; STIMULATION; GLUCOSE; SAFETY; GIP;
D O I
10.1111/jdi.13598
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/Introduction Differences in the glucose-lowering mechanisms of glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been noted. Clarifying these differences could facilitate the choice of optimal drugs for individuals with type 2 diabetes and requires investigation in a clinical setting. Materials and Methods A single-arm, prospective, observational study was conducted to evaluate the effects of various GLP-1RAs on postprandial glucose excursion, secretions of insulin and glucagon as well as on the gastric emptying rate. Participants were subjected to meal tolerance tests before and 2 weeks and 12 weeks after GLP-1RA initiation. Effects on postprandial secretions of glucose-dependent insulinotropic polypeptide (GIP) and apolipoprotein B48 were also investigated. Results Eighteen subjects with type 2 diabetes received one of three GLP-1RAs, i.e., lixisenatide, n = 7; liraglutide, n = 6; or dulaglutide, n = 5. While 12-week administration of all of the GLP-1RAs significantly reduced HbA1c, only lixisenatide and liraglutide, but not dulaglutide, significantly reduced body weight. Postprandial glucose elevation was improved by all of the GLP-1RAs. Postprandial insulin levels were suppressed by lixisenatide, while insulin levels were enhanced by liraglutide. Postprandial glucagon levels were suppressed by lixisenatide. The gastric emptying rate was significantly delayed by lixisenatide, while liraglutide and dulaglutide had limited effects on gastric emptying. GIP secretion was suppressed by lixisenatide and liraglutide. Apolipoprotein B48 secretion was suppressed by all of the GLP-1RAs. Conclusions All of the GLP-1RAs were found to improve HbA1c in a 12-week prospective observational study in Japanese individuals with type 2 diabetes. However, differences in the mechanisms of the glucose-lowering effects and body weight reduction were observed.
引用
收藏
页码:2162 / 2171
页数:10
相关论文
共 50 条
  • [41] Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
    Bethel, M. Angelyn
    Patel, Rishi A.
    Merrill, Peter
    Lokhnygina, Yuliya
    Buse, John B.
    Mentz, Robert J.
    Pagidipati, Neha J.
    Chan, Juliana C.
    Gustavson, Stephanie M.
    Iqbal, Nayyar
    Maggioni, Aldo P.
    Ohman, Peter
    Poulter, Neil R.
    Ramachandran, Ambady
    Zinman, Bernard
    Hernandez, Adrian F.
    Holman, Rury R.
    LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (02) : 105 - 113
  • [42] The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists
    Fang, Haowen
    Niu, Bing
    Chen, Qin
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (20) : 2921 - 2943
  • [43] Glucagon-like peptide-1 receptor agonists and kidney outcomes
    MacIsaac, Richard J.
    Trevella, Philippa
    Ekinci, Elif I.
    JOURNAL OF DIABETES, 2024, 16 (10)
  • [44] Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity
    Jensterle, Mojca
    Janez, Andrej
    HORMONE RESEARCH IN PAEDIATRICS, 2023, 96 (06): : 599 - 608
  • [45] Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials
    Varin, Elodie M.
    McLean, Brent A.
    Lovshin, Julie A.
    CANADIAN JOURNAL OF DIABETES, 2020, 44 (01) : 68 - 77
  • [46] Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future
    Ferrari, Filipe
    Scheffel, Rafael S.
    Martins, Vitor M.
    Santos, Raul D.
    Stein, Ricardo
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2022, 22 (04) : 363 - 383
  • [47] Glucagon-like peptide-1 receptor agonists for improving cardiorenal outcomes in type 1 diabetes mellitus?
    Popovic, Djordje S. S.
    Stoian, Anca Pantea
    Papanas, Nikolaos
    ENDOCRINE, 2023, 80 (01) : 232 - 233
  • [48] Glucagon-like peptide-1 receptor agonists discontinuation is higher in individuals with overweight and obesity without type 2 diabetes
    Grosicki, Gregory J.
    Thomas, J. Graham
    Dhurandhar, Nikhil V.
    Lofton, Holly
    Heymsfield, Steven B.
    Jonnalagadda, Satya S.
    DIABETES OBESITY & METABOLISM, 2025, 27 (03) : 1597 - 1600
  • [49] Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus
    Guyton, Justinne
    Jeon, Michelle
    Brooks, Amie
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (21) : 1739 - 1748
  • [50] Effects of glucagon-like peptide-1 receptor agonists on major coronary events in patients with type 2 diabetes
    Guo, Xueyuan
    Sang, Caihua
    Tang, Ribo
    Jiang, Chenxi
    Li, Songnan
    Liu, Nian
    Long, Deyong
    Du, Xin
    Dong, Jianzeng
    Ma, Changsheng
    DIABETES OBESITY & METABOLISM, 2023, 25 : 53 - 63